Vlad Coric, Biohaven CEO
A pair of storied neuroscience biotechs looks to raise nearly $450M combined (and maybe more) via public offerings
In late September, Biogen and Eisai blew life back into the amyloid hypothesis with a successful readout of their Phase III study on the Alzheimer’s drug lecanemab. Just a week later, Amylyx gained approval of its ALS drug (followed by controversy over its price), marking two landmark events in the neuroscience field that has been plagued by decades of failure across the board. Only in the past few years has money begun to flow into the field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
